GPC3 and hepatocellular carcinoma: A preclinical study performed by Ludwig et al. investigated the therapeutic efficacy of the already mentioned GPC3-targeted mAb αGPC3, radiolabeled with the beta-minus-emitter nuclide yttrium-90 (90Y) in an HCC model [31].